Evidence map›Paper›PMID 40788167›Full record

ArticleMolecular imaging and radionuclide therapy2025

Performance of

Özge Ulaş, Zekiye Hasbek

Abstract read
In one paragraph

Article in Molecular imaging and radionuclide therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Özge UlaşTokat Gaziosmanpaşa University Faculty of Medicine, Department of Nuclear Medicine, Tokat, Türkiye.ORCID 0000-0002-8687-5769
Zekiye HasbekSivas Cumhuriyet University Faculty of Medicine, Department of Nuclear Medicine, Sivas, Türkiye.ORCID 0000-0002-8119-3363

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study was to evaluate the relationship between Galium-68 prostate-specific membrane antigen positron emission tomography combined with computed tomography ( Methods: In the present study, we included 112 patients diagnosed with prostate cancer between 2020 and 2024. These patients underwent Results: No significant correlation was observed between body mass index (BMI) classification and prostate gland maximum standard uptake values (SUV Conclusion: PSA levels may assist in estimating whether metastases are local or distant. However, due to the weak inverse correlation between BMI and PSA, it is important that low PSA levels may not necessarily indicate localized disease during clinical evaluation.

Indexed as

68Ga-PSMA PET/CTBMID’Amico risk classificationProstate cancerPSA

Identifiers

PMID40788167
PMCPMC12505181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.